<DOC>
	<DOCNO>NCT02330003</DOCNO>
	<brief_summary>The purpose study evaluate safety IL-YANG Inactivated Split Influenza Vaccine ( IL-YANG FLU Vaccine Prefilled Syringe INJ . ) comparison Fluarix Prefilled Syringe ( inactivated split influenza vaccine ) single-dose intramuscular administration .</brief_summary>
	<brief_title>Phase 1 Study Assess Safety Inactivated Split Influenza Vaccine Control Vaccine Korean Volunteer</brief_title>
	<detailed_description>This randomize , open-label , active-controlled clinical study . After provide voluntary write informed consent , subject underwent protocol-specific assessment test within 4 week prior administration study vaccine , meet inclusion/exclusion criterion randomize sequentially test group comparator group accord pre-generated randomization code . To investigate safety study drug two-dose regimen child , test group receive another dose 28 day first dose . The investigator evaluate safety immunogenicity subject throughout study . Safety assessment perform 28 day first dose ( Visit 4 , End-of-Study Visit ) comparator group receive single-dose regimen Fluarix Prefilled Syringe , test group receive two-dose regimen test drug , 28 day first dose ( Visit 4 ) 28 day second dose ( Visit 6 , End-of-Study Visit ) . Subjects instruct record adverse event occur vaccination Patient Diary Card . For immunogenicity assessment , antibody titer test perform prior dose Visit 2 ( baseline ) 28 day ( Visit 4 ) first vaccination test group comparator group .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male subject 20 55 year age screen Body weight ≥ 55kg within ±20 % ideal body weight ( ideal body weight = ( height cm 100 ) *0.9 ) screen Subjects congenital chronic disease consider suitable study screen assessment ( investigator 's opinion , medical history , physical examination , laboratory test , chest Xray , ECG ) conduct within 28 day prior vaccination Subjects give , fully understood , information study , make voluntary decision , provide write informed consent , participate study comply applicable study requirement Subjects know suspected infection HAV , HBV , HCV , HIV VDRL Subjects concurrent past history immune deficiency disease Subject participate blood donation within 1 week prior vaccination , plan participate blood donation Day 1 Month 7 postvaccination Subject history GuillainBarre syndrome Subject hemophilia thrombocytopenia , treat anticoagulant , increased risk serious bleed intramuscular injection Subjects concurrent past history , malignant tumor internal organ blood vessel skin metastasis Subjects know allergy drug , food latex , history anaphylaxis Subjects acute fever body temperature &gt; 38.0 Cº within 72 hour prior administration study vaccine symptom suspect acute disease within 14 day prior administration study vaccine Subjects receive another experimental drug vaccine within 28 day administration study vaccine plan receive another experimental drug vaccine study . Subjects previously receive immunoglobulin bloodderived product within last 3 month prior administration study vaccine , expect treat immunoglobulin bloodderived product study Subjects receive , schedule receive , systemic immunosuppressive therapy , radiation therapy highdose corticosteroid therapy within last 6 month prior administration study Subjects history , suspect , drug abuse base subject interview physical examination . Subjects excessive consumption caffeine alcohol excessive smoking Subject know allergy egg , chicken , component study vaccine Subjects investigator 's opinion , may suitable vaccination may interfere objective assessment study outcome .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza vaccine</keyword>
	<keyword>Split influenza vaccine</keyword>
	<keyword>Seasonal influenza vaccine</keyword>
</DOC>